Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to Develop Therapies Modulating RNA Splicing

FDA to Refuse Celgene for Filling Ozanimod’s NDA for the Treatment of Relapsing Multiple Sclerosis

Shots:

  • Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune disorder, oncology, and immuno-oncology targets. Post option exercising, Celgene will be responsible for further development and commercialization of products
  • In 2018, the companies collaborated to discover and develop therapies utilizing Skyhawk’s STAR technology platform for the treatment of autoimmune disorders, oncology, and immuno-oncology diseases
  • Skyhawk’s SkySTAR (Small molecule Therapeutics for Alternative splicing of RNA platform) allows identifying of druggable sites and unique chemical matter for correcting mRNA mis-splicing resulting in novel therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance